Opportunities for clinical research in meningioma

Journal of Neuro-Oncology

Volumn 99, Issue 3, 2010, Pages 417-422

  Vogelbaum, Michael A ^d   Leland Rogers, C ^a   Linskey, Mark A ^b   Mehta, Minesh P ^c  

^a GammaWest Cancer Services   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^d NONE

Author keywords

Clinical trial; Incidence; Meningioma; Outcomes

Indexed keywords

ERLOTINIB; GEFITINIB; HYDROXYUREA; IFOSFAMIDE; IMATINIB; MESNA; MIFEPRISTONE; TAMOXIFEN;

CANCER GRADING; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL RESEARCH; CLINICAL TRIAL; DRUG DOSE INCREASE; HUMAN; INCIDENCE; MENINGIOMA; MULTIPLE CYCLE TREATMENT; NEUROIMAGING; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; QUALITY OF LIFE; REVIEW;

BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; HUMANS; MENINGEAL NEOPLASMS; MENINGIOMA; WORLD HEALTH ORGANIZATION;

EID: 77957602523     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-010-0375-6     Document Type: Review

References (23)

1. D Simpson 1957 The recurrence of intracranial meningiomas after surgical treatment J Neurol Neurosurg Psychiatry 20 1 22 39 1:STN:280: DyaG2s%2Flt1yksQ%3D%3D 10.1136/jnnp.20.1.22 13406590
2. T Kinjo O al-Mefty I Kanaan 1993 Grade zero removal of supratentorial convexity meningiomas Neurosurgery 33 3 394 399 1:STN:280:DyaK2c%2FitVWhtg%3D%3D 10.1227/00006123-199309000-00007 8413869
3. S Stafford A Perry V Suman F Meyer B Scheithauer C Lohse, et al. 1998 Primarily resected meningiomas: outcome and prognostic factors in 581 Mayo Clinic patients, 1978 through 1988 Mayo Clin Proc 73 10 936 942 1:STN:280:DyaK1M%2FgsVSjug%3D%3D 10.4065/73.10.936 9787740
4. A Perry B Scheithauer S Stafford C Lohse P Wollan 1999 "Malignancy" in meningiomas: a clinicopathologic study of 116 patients, with grading implications Cancer 85 9 2046 2056 1:STN:280: DyaK1M3jslOmug%3D%3D 10223247
5. J Kuratsu M Kochi Y Ushio 2000 Incidence and clinical features of asymptomatic meningiomas J Neurosurg 92 5 766 770 1:STN:280: DC%2BD3c3lt1alsQ%3D%3D 10.3171/jns.2000.92.5.0766 10794289
6. E Claus M Bondy J Schildkraut J Wiemels M Wrensch P Black 2005 Epidemiology of intracranial meningioma Neurosurgery 57 6 1088 1095 10.1227/01.NEU.0000188281.91351.B9 16331155 (Pubitemid 41827383)
7. J Jääskeläinen 1986 Seemingly complete removal of histologically benign intracranial meningioma: late recurrence rate and factors predicting recurrence in 657 patients. A multivariate analysis Surg Neurol 26 5 461 469 10.1016/0090-3019(86)90259-4 3764651 (Pubitemid 16006137)
8. H Jung H Yoo S Paek K Choi 2000 Long-term outcome and growth rate of subtotally resected petroclival meningiomas: experience with 38 cases Neurosurgery 46 3 567 574 1:STN:280:DC%2BD3c7ot1Oksw%3D%3D 10.1097/00006123- 200003000-00008 10719852
9. BJ Taylor RJ Marcus W Friedman WJ Ballinger R Million 1988 The meningioma controversy: postoperative radiation therapy Int J Radiat Oncol Biol Phys 15 2 299 304 3403313
10. R Miralbell R Linggood S de la Monte K Convery J Munzenrider R Mirimanoff 1992 The role of radiotherapy in the treatment of subtotally resected benign meningiomas J Neurooncol 13 2 157 164 1:STN:280:DyaK3s%2FlslKrtA%3D%3D 10.1007/BF00172765 1432033
11. K Condra J Buatti W Mendenhall W Friedman RJ Marcus A Rhoton 1997 Benign meningiomas: primary treatment selection affects survival Int J Radiat Oncol Biol Phys 39 2 427 436 1:STN:280:DyaK2svlt1GgsQ%3D%3D 9308947
12. S Smith S Boddu D Macarthur 2007 Atypical meningiomas: WHO moved the goalposts? Br J Neurosurg 21 6 588 592 1:STN:280:DC%2BD2sjjsV2lsA%3D%3D 10.1080/02688690701684246 18071986 (Pubitemid 350249214)
13. J Willis C Smith J Ironside S Erridge I Whittle D Everington 2005 The accuracy of meningioma grading: a 10-year retrospective audit Neuropathol Appl Neurobiol 31 2 141 149 1:STN:280:DC%2BD2M7ktVGqtw%3D%3D 10.1111/j.1365-2990. 2004.00621.x 15771707 (Pubitemid 40444915)
14. M Riemenschneider A Perry G Reifenberger 2006 Histological classification and molecular genetics of meningiomas Lancet Neurol 12 1045 1054 10.1016/S1474-4422(06)70625-1 (Pubitemid 44709980)
15. B Pearson J Markert W Fisher B Guthrie J Fiveash C Palmer, et al. 2008 Hitting a moving target: evolution of a treatment paradigm for atypical meningiomas amid changing diagnostic criteria Neurosurg Focus 24 5 E3 10.3171/FOC/2008/24/5/E3 18447742
16. M Aghi B Carter G Cosgrove R Ojemann S Amin-Hanjani R Martuza, et al. 2009 Long-term recurrence rates of atypical meningiomas after gross total resection with or without postoperative adjuvant radiation Neurosurgery 64 1 56 60 10.1227/01.NEU.0000330399.55586.63 19145156
17. J Ayerbe R Lobato J de la Cruz R Alday J Rivas P Gómez, et al. 1999 Risk factors predicting recurrence in patients operated on for intracranial meningioma. A multivariate analysis Acta Neurochir (Wien) 141 9 921 932 1:STN:280:DyaK1Mvls1Cksg%3D%3D 10.1007/s007010050398 (Pubitemid 29462215)
18. J Flickinger D Kondziolka A Maitz L Lunsford 2003 Gamma knife radiosurgery of imaging-diagnosed intracranial meningioma Int J Radiat Oncol Biol Phys 56 3 801 806 12788188 (Pubitemid 36677375)
19. B Pollock 2003 Stereotactic radiosurgery for intracranial meningiomas: indications and results Neurosurg Focus 14 5 E4 10.3171/foc.2003.14.5.5 15669815
20. J Goodwin J Crowley H Eyre B Stafford K Jaeckle J Townsend 1993 A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a Southwest Oncology Group study J Neurooncol 15 1 75 77 1:STN:280: DyaK3s3gtl2htg%3D%3D 10.1007/BF01050266 8455065 (Pubitemid 23049702)
21. Grunberg SM, Rankin C, Townsend J, Ahmadi J, Feun L, Fredericks R, Russell C, Kabbinavar F, Barger GR, Stelzer KJ, Southwest Oncology Group, Eastern Cooperative Group (2001) Phase III double-blind randomized placebo-controlled study of mifepristone (RU) for the treatment of unresectable meningioma. In: Proceedings of the American Society of Clinical Oncology 20 (abstract 222)
22. P Wen W Yung K Lamborn A Norden T Cloughesy L Abrey, et al. 2009 Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08) Neuro Oncol 11 6 853 860 1:CAS:528: DC%2BC3cXotVOruw%3D%3D 10.1215/15228517-2009-010 19293394
23. A Norden J Raizer L Abrey K Lamborn A Lassman S Chang, et al. 2010 Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma J Neurooncol 96 2 211 217 1:CAS:528:DC%2BC3cXpsVSjsw%3D%3D 10.1007/s11060-009- 9948-7 19562255